Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
CBX-12
DRUG
2 trials
Sponsors
Cybrexa Therapeutics
Conditions
Appendix Cancer
Breast Cancer
Colorectal Cancer
Epithelial Ovarian Cancer
Esophagus Cancer
Gastric Cancer
Non-small Cell Lung Cancer
Pancreas Cancer
+6 more
Phase 1
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Completed
NCT04902872
Cybrexa Therapeutics
Appendix Cancer, Breast Cancer, Colorectal Cancer +9
Start: 2021-05-03
End: 2025-06-24
Updated: 2026-08-20
Phase 2
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Terminated
NCT06315491
Cybrexa Therapeutics
Platinum-resistant Ovarian Cancer, Refractory Ovarian Carcinoma
Start: 2024-09-25
End: 2025-10-31
Updated: 2026-08-20
Related Papers
Pilot study of CBX-12 pharmacodynamics in patients with advanced solid tumors.
Journal of Clinical Oncology
2024-06-01
1 citations
CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients (pts) with advanced or metastatic solid tumors.
Journal of Clinical Oncology
2023-06-01
5 citations